Complete and long‐lasting cytologic and molecular remission of FIP1L1‐PDGFRA‐positive acute eosinophil myeloid leukaemia, treated with low‐dose imatinib monotherapy
Myeloproliferative neoplasms associated with FIP1L1‐PDGFR rearrangements represent a rare subset of myeloid and lymphoid malignancies, characterised by the presence of eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 genes. The fusion product of such genes is a tyrosine kinase oncoprotein sensitive to imatinib, which to date results to be the standard of care for FIP1L1‐PDGFRA‐positive chronic myeloproliferative disorders with eosinophilia. However, the coexistence of FIP1L1‐PDGFRA rearrangement associated with acute myeloid leukaemia is extremely rare. Here, we report a rare case of FIP1L1‐PDGFRA‐positive acute myeloid leukaemia, with marked peripheral blood and bone marrow eosinophilia, treated with low dose of imatinib monotherapy, achieving a rapid and long‐lasting complete cytologic and molecular remission, without need for intensive chemotherapy.
No Supplementary Data
No Article Media